CombinAble.AI

Tailored Antibody Optimization

Health Tech & Life Sciences
Acquired by insitro on Jan 2026
Follow

Company Overview

Snapshot

Founded in August 2023 by Daria Kokh, CombinAble.AI operates with 1–10 employees. The company was acquired by insitro in January 2026, following a funding round in March 2024.

Business overview

CombinAble.AI revolutionizes therapeutic design through its AI platform, which facilitates the rapid in silico development of complex antibody formats, including bi-specifics, tri-specifics, and T-cell engagers. This technology significantly accelerates the development timeline for best-in-class therapeutics, serving the biopharmaceutical, biotechnology, and pharmaceutical industries within the Health Tech & Life Sciences sector.

Strategic signal

CombinAble.AI was acquired by insitro in January 2026, signaling a significant validation of its AI platform for drug discovery and design. This acquisition allows insitro to complete its full-stack, modality-agnostic AI platform, indicating a strategic move to integrate advanced antibody optimization capabilities into broader drug development efforts. For investors, this highlights the increasing value and demand for AI-driven solutions in accelerating therapeutic design and development.

Log in to access full profile

Company Intelligence Q&A

What was a significant recent corporate development for CombinAble.AI?
CombinAble.AI was acquired by insitro in January 2026. This acquisition aimed to complete insitro's full-stack, modality-agnostic AI platform for drug discovery and design.
When was CombinAble.AI founded and by whom?
CombinAble.AI was founded in August 2023 by Co-founder & CEO Daria Kokh.
What is CombinAble.AI's primary focus in therapeutic design?
CombinAble.AI focuses on the rapid in silico development of complex antibody formats, including bi-specifics, tri-specifics, and T-cell engagers, using its unique AI platform.
What is the reported benefit of CombinAble.AI's platform for drug development?
The platform enables the development of best-in-class therapeutics in approximately four months, significantly faster than traditional methods, providing a competitive advantage for complex biologics.
Log in to access full profile